ArticleTherapeutic advances in medical oncology2019

Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study.

Vincenzo Adamo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.